(+)-VINCRISTINE

Stage III Pancreatic Cancer

Dai, GuanghaiSmall moleculePhase 3Active

BBB

72/ 100

Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence: 60/ 100
Competitive Position: 95/ 100

Competitive context

8 Active assets in the Stage III Pancreatic Cancer cohort.

Asset / Sponsor	Phase	Rating
Irinotecan NRG Oncology	Phase 3	BB
FLUTICASONE Barbara Ann Karmanos Cancer Institute	Phase 1/2	B
Sargramostim Barbara Ann Karmanos Cancer Institute	Phase 1/2	B
Cediranib National Cancer Institute (NCI)	Phase 2	B
Nelfinavir University of Nebraska	Phase 2	B

View all 21 →

Same molecule, other indications

(+)-VINCRISTINE is also rated in:

anaplastic large cell lymphomaDormant

BBB

Indicative ·

78 / 100

mycosis fungoidesDormant

BBB

Indicative ·

78 / 100

adult acute lymphoblastic leukemiaDormant

BBB

Indicative ·

77 / 100

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.